BACKGROUND: Existing prostate cancer cell lines have limitations. METHODS: Cells were characterized using Western blotting, immunohistochemistry, invasion into Matrigel, and by studying xenograft tumors. RESULTS: We describe a cell line (PacMetUT1) isolated from a lymph node of a 57-year-old male with prostate cancer. Compared to existing prostate cancer cell lines, the growth rate of PacMetUT1 xenograft tumors is slower with tumors occurring at injection sites and with metastases to lung and liver. Androgen receptor (AR) was detected in vivo by Western blotting and the cells responded to methyltrienolone (R1881). PacMetUT1 cells are more invasive in Matrigel than DU-145, PC-3, and LNCaP cells, and showed greater anchorage-independent growth in soft agar. The cells do not express prostate specific antigen (PSA) in vitro or in xenografts. However, the green fluorescent protein (GFP) gene was introduced and stably expressed in PacMetUT1 cells, allowing tumor imaging in vivo. Xenograft tumors show epithelial features and are positive for keratin, epithelial membrane antigen, EGF receptor, and E cadherin. In contrast, fibroblast markers vimentin, desmin, and Factor VIII, were negative. Karyotyping showed losses of 6p, 7q, 8p, 18q, and 22q, and gains of 8q and 9q; additional genetic material was observed at 2q and 12p. CONCLUSION: The PacMetUT1 cell line allows metastases to be assessed using a single animal model. Because of its slower growth, PacMetUT1 more closely mimics the human disease. Studies of tumor progression or metastasis can be conducted over a longer period of time. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Existing prostate cancer cell lines have limitations. METHODS: Cells were characterized using Western blotting, immunohistochemistry, invasion into Matrigel, and by studying xenograft tumors. RESULTS: We describe a cell line (PacMetUT1) isolated from a lymph node of a 57-year-old male with prostate cancer. Compared to existing prostate cancer cell lines, the growth rate of PacMetUT1 xenograft tumors is slower with tumors occurring at injection sites and with metastases to lung and liver. Androgen receptor (AR) was detected in vivo by Western blotting and the cells responded to methyltrienolone (R1881). PacMetUT1 cells are more invasive in Matrigel than DU-145, PC-3, and LNCaP cells, and showed greater anchorage-independent growth in soft agar. The cells do not express prostate specific antigen (PSA) in vitro or in xenografts. However, the green fluorescent protein (GFP) gene was introduced and stably expressed in PacMetUT1 cells, allowing tumor imaging in vivo. Xenograft tumors show epithelial features and are positive for keratin, epithelial membrane antigen, EGF receptor, and E cadherin. In contrast, fibroblast markers vimentin, desmin, and Factor VIII, were negative. Karyotyping showed losses of 6p, 7q, 8p, 18q, and 22q, and gains of 8q and 9q; additional genetic material was observed at 2q and 12p. CONCLUSION: The PacMetUT1 cell line allows metastases to be assessed using a single animal model. Because of its slower growth, PacMetUT1 more closely mimics the human disease. Studies of tumor progression or metastasis can be conducted over a longer period of time. (c) 2008 Wiley-Liss, Inc.
Authors: Dazhi Yang; Noemi Kedei; Luowei Li; Juan Tao; Julia F Velasquez; Aleksandra M Michalowski; Balázs I Tóth; Rita Marincsák; Attila Varga; Tamás Bíró; Stuart H Yuspa; Peter M Blumberg Journal: Cancer Res Date: 2010-09-28 Impact factor: 12.701
Authors: Mark P Labrecque; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Bryce Lakely; Holly M Nguyen; Yu C Yang; Rui M Gil da Costa; Arja Kaipainen; Roger Coleman; Celestia S Higano; Evan Y Yu; Heather H Cheng; Elahe A Mostaghel; Bruce Montgomery; Michael T Schweizer; Andrew C Hsieh; Daniel W Lin; Eva Corey; Peter S Nelson; Colm Morrissey Journal: J Clin Invest Date: 2019-07-30 Impact factor: 14.808
Authors: Holly Lewis; Raymond Lance; Dean Troyer; Hind Beydoun; Melissa Hadley; Joseph Orians; Tiffany Benzine; Kenya Madric; O John Semmes; Richard Drake; Aurora Esquela-Kerscher Journal: Cell Cycle Date: 2013-11-07 Impact factor: 4.534
Authors: John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade Journal: Prostate Date: 2012-03-06 Impact factor: 4.104
Authors: Sweta Mishra; Yuping Tang; Long Wang; Linda deGraffenried; I-Tien Yeh; Sherry Werner; Dean Troyer; John A Copland; Lu-Zhe Sun Journal: Prostate Date: 2011-02-14 Impact factor: 4.104
Authors: Eric G Bluemn; Ilsa M Coleman; Jared M Lucas; Roger T Coleman; Susana Hernandez-Lopez; Robin Tharakan; Daniella Bianchi-Frias; Ruth F Dumpit; Arja Kaipainen; Alexandra N Corella; Yu Chi Yang; Michael D Nyquist; Elahe Mostaghel; Andrew C Hsieh; Xiaotun Zhang; Eva Corey; Lisha G Brown; Holly M Nguyen; Kenneth Pienta; Michael Ittmann; Michael Schweizer; Lawrence D True; David Wise; Paul S Rennie; Robert L Vessella; Colm Morrissey; Peter S Nelson Journal: Cancer Cell Date: 2017-10-09 Impact factor: 31.743